Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  3. The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Michel Fabbro
  • Kathleen N Moore
  • Anne Dørum
  • Anna V Tinker
  • Sven Mahner
  • Isabel Bover
  • Susana Banerjee
  • Germana Tognon
  • Frederic Goffin
  • Ronnie Shapira-Frommer
  • Robert M Wenham
  • Kristina Hellman
  • Diane Provencher
  • Philipp Harter
  • Isabel Palacio Vázquez
  • Philippe Follana
  • Mario J Pineda
  • Mansoor R Mirza
  • Sebastien J Hazard
  • Ursula A Matulonis
View graph of relations

OBJECTIVE: To analyze the safety and efficacy of niraparib in patients aged ≥70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial.

METHODS: The trial enrolled 2 independent cohorts with histologically diagnosed recurrent ovarian, fallopian tube, or peritoneal cancer who responded to platinum rechallenge, on the basis of germline breast cancer susceptibility gene mutation (gBRCAmut) status. Patients were randomized 2:1 to receive niraparib (300 mg) or placebo once daily until disease progression. The primary endpoint was progression-free survival (PFS) by blinded independent central review. Adverse events (AEs) of special interest were based on the known safety profile of poly(ADP-ribose) polymerase inhibitors.

RESULTS: Patients aged ≥70 years in the gBRCAmut cohort receiving niraparib (n = 14) had not yet reached a median PFS compared with a median PFS of 3.7 months for the same age group in the placebo arm (hazard ratio [HR], 0.09 [95% confidence interval (CI), 0.01 to 0.73]). Non-gBRCAmut patients aged ≥70 years receiving niraparib (n = 47) had a median PFS of 11.3 months compared with 3.8 months in the placebo arm (HR, 0.35 [95% CI, 0.18 to 0.71]). Median duration of follow-up in the niraparib arm was 17.3 months in patients ≥70 years and 17.2 months in patients <70 years. Frequency, severity of AEs, and dose reductions in the niraparib arm were similar in patients aged <70 and ≥ 70 years population. The most common grade ≥ 3 AEs in patients ≥70 years were hematologic: thrombocytopenia event (34.4%), anemia event (13.1%), and neutropenia event (16.4%).

CONCLUSIONS: For patients ≥70 years of age receiving niraparib as maintenance treatment in the ENGOT-OV16/NOVA trial, PFS benefits and incidence of any grade or serious treatment-emergent AEs were comparable to results in the younger population. Use of niraparib should be considered in this population.

Original languageEnglish
JournalGynecologic Oncology
Volume152
Issue number3
Pages (from-to)560-567
Number of pages8
ISSN0090-8258
DOIs
Publication statusPublished - Mar 2019

    Research areas

  • Adult, Aged, Aged, 80 and over, Female, Humans, Indazoles/adverse effects, Maintenance Chemotherapy, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Ovarian Neoplasms/drug therapy, Patient Reported Outcome Measures, Piperidines/adverse effects, Poly(ADP-ribose) Polymerase Inhibitors/adverse effects

ID: 59074772